Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) EBIT Margin (2016 - 2025)

Northwest Biotherapeutics' EBIT Margin history spans 16 years, with the latest figure at 4944.64% for Q4 2025.

  • Quarterly results put EBIT Margin at 4944.64% for Q4 2025, down 822246.0% from a year ago — trailing twelve months through Dec 2025 was 956.6% (up 31641.0% YoY), and the annual figure for FY2025 was 956.6%, up 31641.0%.
  • EBIT Margin for Q4 2025 was 4944.64% at Northwest Biotherapeutics, up from 7160.0% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 13167.1% in Q4 2024 to a low of 11281.68% in Q2 2025.
  • The 5-year median for EBIT Margin is 3424.31% (2024), against an average of 3433.48%.
  • The sharpest move saw EBIT Margin skyrocketed 37381755bps in 2021, then crashed -822246bps in 2025.
  • Year by year, EBIT Margin stood at 2871.14% in 2021, then fell by -6bps to 3044.89% in 2022, then decreased by -12bps to 3402.7% in 2023, then skyrocketed by 487bps to 13167.1% in 2024, then tumbled by -62bps to 4944.64% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 4944.64%, 7160.0%, and 11281.68% for Q4 2025, Q3 2025, and Q2 2025 respectively.